XML 121 R97.htm IDEA: XBRL DOCUMENT v3.5.0.2
Segment Information (Reconciliation Of Segment Information To Total Consolidated Information) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2016
Sep. 30, 2015
Sep. 30, 2016
Sep. 30, 2015
Segment Reporting Information [Line Items]        
Total revenues $ 3,057.1 $ 2,695.2 $ 7,809.1 $ 6,938.6
Segment profitability (loss) (130.7) 601.1 385.8 1,037.0
Generics Segment        
Segment Reporting Information [Line Items]        
Total revenues 2,625.0 2,249.9 6,709.4 5,968.8
Specialty Segment        
Segment Reporting Information [Line Items]        
Total revenues 432.1 445.3 1,099.7 969.8
Intersegment        
Segment Reporting Information [Line Items]        
Total revenues 0.0 0.0 0.0 0.0
Intersegment | Generics Segment        
Segment Reporting Information [Line Items]        
Total revenues 27.4 1.4 29.5 5.2
Intersegment | Specialty Segment        
Segment Reporting Information [Line Items]        
Total revenues 7.2 1.2 13.7 5.8
Operating Segment        
Segment Reporting Information [Line Items]        
Total revenues 3,057.1 2,695.2 7,809.1 6,938.6
Operating Segment | Generics Segment        
Segment Reporting Information [Line Items]        
Total revenues 2,652.4 2,251.3 6,738.9 5,974.0
Segment profitability (loss) 799.3 788.5 1,923.7 1,834.0
Operating Segment | Specialty Segment        
Segment Reporting Information [Line Items]        
Total revenues 439.3 446.5 1,113.4 975.6
Segment profitability (loss) 278.2 258.2 658.3 524.2
Corporate / Other        
Segment Reporting Information [Line Items]        
Total revenues [1] (34.6) (2.6) (43.2) (11.0)
Segment profitability (loss) [1] $ (1,208.2) $ (445.6) $ (2,196.2) $ (1,321.2)
[1] Includes certain corporate general and administrative and R&D expenses; litigation settlements and other contingencies, net, which for the three and nine months ended September 30, 2016 included the Medicaid Drug Rebate Program Settlement and the Strides Settlement, as discussed further in Note 18 Contingencies; certain intercompany transactions, including eliminations; amortization of intangible assets and certain purchase accounting items; impairment charges; and other expenses not directly attributable to segments.